Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Incyte (INCY) and Oncology Institute (TOI)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report), Incyte (INCY – Research Report) and Oncology Institute (TOI – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Roche Holding AG (RHHVF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Roche Holding AG, with a price target of CHF340.00. The company’s shares closed last Friday at $439.07.
According to TipRanks.com, Papadakis is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Roche Holding AG with a $448.44 average price target, implying a 0.0% downside from current levels. In a report issued on March 2, J.P. Morgan also maintained a Hold rating on the stock with a CHF350.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Incyte (INCY)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Incyte, with a price target of $135.00. The company’s shares closed last Friday at $95.94.
According to TipRanks.com, Kapoor is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $110.53 average price target, implying a 14.9% upside from current levels. In a report issued on March 2, TD Cowen also maintained a Buy rating on the stock with a $123.00 price target.
Oncology Institute (TOI)
In a report released today, Matthew Shea from Needham reiterated a Buy rating on Oncology Institute, with a price target of $5.00. The company’s shares closed last Friday at $2.78.
According to TipRanks.com, Shea ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oncology Institute with a $5.00 average price target.
